These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
315 related articles for article (PubMed ID: 17069061)
41. Gastroretentive carbidopa/levodopa, DM-1992, for the treatment of advanced Parkinson's disease. Verhagen Metman L; Stover N; Chen C; Cowles VE; Sweeney M Mov Disord; 2015 Aug; 30(9):1222-8. PubMed ID: 25847690 [TBL] [Abstract][Full Text] [Related]
42. An Observational Study of the Effect of Levodopa-Carbidopa Intestinal Gel on Activities of Daily Living and Quality of Life in Advanced Parkinson's Disease Patients. Krüger R; Lingor P; Doskas T; Henselmans JML; Danielsen EH; de Fabregues O; Stefani A; Sensken SC; Parra JC; Onuk K; Yegin A; Antonini A Adv Ther; 2017 Jul; 34(7):1741-1752. PubMed ID: 28631218 [TBL] [Abstract][Full Text] [Related]
43. Double-blind study of the actively transported levodopa prodrug XP21279 in Parkinson's disease. LeWitt PA; Huff FJ; Hauser RA; Chen D; Lissin D; Zomorodi K; Cundy KC Mov Disord; 2014 Jan; 29(1):75-82. PubMed ID: 24339234 [TBL] [Abstract][Full Text] [Related]
44. [A combined preparation stalevo in Parkinson's disease: a 5-year experience of continuous dopaminergic stimulation]. Fedotova EIu; Karabanov AV; Poleshchuk VV; Polevaia EV; Mirkasimov AF; Zagorovskaia TB; Ivanova-Smolenskaia IA; Illarioshkin SN Zh Nevrol Psikhiatr Im S S Korsakova; 2012; 112(5):50-5. PubMed ID: 22951782 [TBL] [Abstract][Full Text] [Related]
49. [Inhibition of the COMPT with entacapone in the treatment of motor fluctuations in Parkinson disease]. Kulisevsky J Neurologia; 1999; 14(7):349-58. PubMed ID: 10570622 [TBL] [Abstract][Full Text] [Related]
50. Clinical experiences with levodopa methylester (melevodopa) in patients with Parkinson disease experiencing motor fluctuations: an open-label observational study. Zangaglia R; Stocchi F; Sciarretta M; Antonini A; Mancini F; Guidi M; Martignoni E; Pacchetti C Clin Neuropharmacol; 2010; 33(2):61-6. PubMed ID: 19935405 [TBL] [Abstract][Full Text] [Related]
51. Comparison of standard carbidopa-levodopa and sustained-release carbidopa-levodopa in Parkinson's disease: pharmacokinetic and quality-of-life measures. Pahwa R; Lyons K; McGuire D; Silverstein P; Zwiebel F; Robischon M; Koller WC Mov Disord; 1997 Sep; 12(5):677-81. PubMed ID: 9380047 [TBL] [Abstract][Full Text] [Related]
52. [The optimization of using levodopa in patients with Parkinson's disease: results of the OPTIMA study]. Datieva VK; Makotrova TA; Levin OS Zh Nevrol Psikhiatr Im S S Korsakova; 2012; 112(10 Pt 2):13-9. PubMed ID: 23250605 [TBL] [Abstract][Full Text] [Related]
53. [Optimization of use of levodopa in Parkinson's disease: role of levodopa-carbidopa-entacapone combination]. Castro A; Valldeoriola F; Linazasoro G; Rodriguez-Oroz MC; Stochi F; Marin C; Rodriguez M; Vaamonde J; Jenner P; Alvarez L; Pavon N; Macias R; Luquin MR; Hernandez B; Grandas F; Gimenez-Roldan S; Tolosa E; Obeso JA Neurologia; 2005 May; 20(4):180-8. PubMed ID: 15891947 [TBL] [Abstract][Full Text] [Related]
54. Inhibition of catechol-O-methyltransferase contributes to more stable levodopa plasma levels. Müller T; Erdmann C; Muhlack S; Bremen D; Przuntek H; Woitalla D Mov Disord; 2006 Mar; 21(3):332-6. PubMed ID: 16211593 [TBL] [Abstract][Full Text] [Related]
55. [Current possibilities of quality of life improvement in the late stages of Parkinson's disease]. Titova NV; Katunina EA Zh Nevrol Psikhiatr Im S S Korsakova; 2015; 115(3):94-100. PubMed ID: 26171484 [TBL] [Abstract][Full Text] [Related]
56. [Nocturnal symptoms of Parkinson's disease and approaches to their correction]. Kulua TK; Fedorova NV Zh Nevrol Psikhiatr Im S S Korsakova; 2013; 113(12):62-6. PubMed ID: 24430037 [TBL] [Abstract][Full Text] [Related]
57. Sinemet CR in Parkinson's disease. Pfeiffer RF; Wilken KE; Glaeske CS; Hofman R Nebr Med J; 1991 Jan; 76(1):8-10. PubMed ID: 1997878 [TBL] [Abstract][Full Text] [Related]